MEDICAL SCIENCE MONITOR

CLINICAL RESEARCH

e-ISSN 1643-3750 © Med Sci Monit, 2018; 24: 2873-2877 DOI: 10.12659/MSM.907418

Received: 2017.10. Accepted: 2017.11. Published: 2018.05.0	07	Relationship Between Carbohydrate Antigen 125 and Coronary Artery Calcification in Patients without Known Coronary Artery Disease					
Authors' Contribution:ABCDEFG1Study Design AB1Data Collection BB2Statistical Analysis CB1Data Interpretation DB1Manuscript Preparation EA3Literature Search FFunds Collection G5			 Department of Cardiology, Beijing Aerospace General Hospital, Beijing, P.R. China Department of Internal Medicine, Urumqi City People's Hospital (Children's Hospital) North Hospital, Urumqi, Xinjiang, P.R. China Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, P.R. China 				
	ling Author: of support:	Peng Hao, e-mail: haopeng_bjaz@sina.com Departmental sources					
Material	ckground: /Methods: Results: nclusions:	coronary artery calcification (CAC) score in The study groups included 348 consecut ease, and who underwent an estimation The clinical and laboratory characteristics tertiles. The CAC score was found to be in p<0.001). Serum CA125 concentrations a ative ones (9.3±4.79 vs. 11.2±7.36, p=0.0 observed (r=0.319, p<0.001) in all particip positively correlated with CAC score in bot Multiple linear regression analysis results ed to CAC score in the study population sitivity C-reactive protein (hs-CRP) were a Serum CA125 concentrations are correlated	e association between serum carbohydrate antigen 125 (CA125) and n patients without known coronary artery disease. ive subjects with chest pain but without known coronary artery dis- of CAC score in our hospital. of all subjects are presented according to serum CA125 concentrations ncreased in the tertiles $(31.6 \pm 82.10, 73.3 \pm 125.6, 122.9 \pm 135.9 \text{ U/mL},$ re increased in calcium-positive patients compared with calcium-neg- 03). A positive correlation between serum CA125 and CAC score was bants. Similarly, the serum concentrations of CA125 were found to be th women and men (r=0.328, p<0.001; r=0.265, p=0.001, respectively). indicated that serum CA125 concentrations are independently relat- beta=0.173, p=0.001), and age, sex, diabetes mellitus, and high-sen- also associated with CAC score in multiple linear regression analysis. teed with CAC score in the population without known coronary artery lered as a marker to estimate CAC in the study population.				
MeSH Keywords: Full-text PDF:		Angioplasty, Balloon, Coronary • CA-19-9 Antigen • Internal Mammary-Coronary Artery Anastomosis https://www.medscimonit.com/abstract/index/idArt/907418					
		1 471 1 2 1 2	2 29				



2873

Background

Coronary artery calcification (CAC) is a part of the atherosclerotic processes and a traditional risk factor of cardiovascular disease in diverse subsets of the population [1]. CAC score has been reported to be linked with coronary artery disease and cardiovascular events [2]. A significant association of the presence of CAC with atherosclerosis burden has been demonstrated by Sangiorgi [3]. Recent studies have demonstrated that CAC is associated with increased morbidity and mortality in patients with chronic obstructive pulmonary disease [4], and is related with mortality in dialysis patients [5]. CAC examined by computerized tomography is a crucial marker of atherosclerotic presence, and is associated with coronary plaque burden [6,7]. Thus, an early estimation of CAC will assist in predicting increased mortality and morbidity in this patient population.

Carbohydrate antigen 125 (CA125) is regarded as a valuable marker for detecting ovarian cancer and predicting patient prognosis [5]. In addition to routine use in clinical ovarian tumors, it has recently been suggested that serum CA125 concentrations are associated with liver cirrhosis, deep endometriosis, and preeclampsia [8-10]. A positive correlation between serum CA125 concentrations and C-reactive protein (CRP) also was found in patients with preeclampsia [11]. On the other hand, increased CA125 concentrations have been reported in patients with heart failure [12]. Higher CA-125 concentrations have been found to be linked with new-onset atrial fibrillation in healthy postmenopausal females [13]. The serum levels of CA-125 can be used to predict the appearance of atrial fibrillation in heart failure patients [14]. Inflammation may be an important factor explaining the associations of serum CA125 with these diseases. Systemic inflammation contributes to the appearance of CAC, and promotes the development of CAC, even in the general population [15], and there are no data to estimate the relationship between serum CA125 and CAC in any population. Therefore, the present study was designed to investigate the association between serum CA125 and CAC scores in patients without known coronary artery disease.

Material and Methods

The study groups included 348 consecutive subjects with chest pain but without known coronary artery disease, and who underwent an estimation of CAC score in our hospital between January 2017 and September 2017. Exclusion criteria were: heart failure, coronary artery disease (including stenocardia and myocardial infarction), atrial fibrillation, cardiomyopathies, renal and liver dysfunction, hemolytic disorders, thyroid disease, acute and chronic inflammatory diseases, neoplastic diseases, immune diseases, current or former smoking, and pregnant woman. Patients who underwent any stress test or coronary angiography before CAC assessment were excluded. The study was approved by the Beijing Aerospace General Hospital Institutional Review Board, and informed consent was obtained from all participants.

Clinical and laboratory data

Fasting blood samples were obtained within 2 h. The laboratory parameters were tested in a single laboratory, including fasting blood glucose (FBG), total protein (TP), alanine transaminase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-sensitivity C-reactive protein (hs-CRP), creatinine (Cr), urea nitrogen (UN), and CA125. Clinical information was obtained from medical records, including sex, age, body mass index (BMI), and other data. All computerized tomography scans were performed on a 128-slice scanner for generating CAC scores.

Statistical analysis

All statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). All data are expressed as percentages or means ± standard deviation, as appropriate. The one-way ANOVA test and chi-square test were used to compare the differences between the 3 groups. The correlations of CA125 with clinical, laboratory, and CAC score were assessed by Pearson or Spearman analysis. Multiple linear regression analysis was used to assess the independent variables affecting the relationship between serum CA125 concentrations and CAC score in the study population. Two-tailed P<0.05 was considered as indicating statistically significant differences.

Results

The clinical and laboratory characteristics of all subjects are presented according to serum CA125 levels tertiles (Table 1). There were statistically significant differences between the 3 groups in age, BMI, TC, HDL-C, Cr, hs-CRP, diabetes mellitus, angiotensin-converting enzyme inhibitors, calcium ion channel blockers, and antidiabetic medications. Of note, the CAC score was found to be increased in the serum CA125 tertiles (31.6±82.10, 73.3±125.6, 122.9±135.9 U/mL, p<0.001) (Figure 1). The serum CA125 concentrations of the study population were grouped according to calcium-positive and calcium-negative, showing that serum CA125 concentrations are increased in calciumpositive patients compared to those who were calcium-negative (9.3±4.79 vs. 11.2±7.36, p=0.003), as shown in Figure 2. No significant differences were observed in other parameters, such as sex, ALT, AST, UN, GLU, TP, TG, LDL-C, hypertension, beta-blockers, and cholesterol-lowering therapy.

	l ≤6.5	ll 6.5–11.7	III 11.7	n Value
	N=114	N=117	N=117	p-Value
Gender (female/male)	74/40	62/55	60/57	0.076
Age(y)	53.9±14.51	57.3±14.89	59.2±14.92	0.015
Body mass index (Kg/m²)	22.9±2.37	23.3±2.91	24.7±3.52	<0.001
Diabetes mellitus	16	27	56	<0.001
Hypertension	41	30	35	0.333
ACEI or ARB	40	36	2	<0.001
Beta- blockers	19	15	16	0.683
Ca channel blockers	19	10	27	0.010
Antidiabetics	31	26	56	<0.001
Cholesterol lowering therapy	11	8	17	0.148
Alanine transaminase (U/L)	16.9±7.32	17.6±7.45	17.8±7.11	0.626
Aspartate aminotransferase (U/L)	18.2±4.24	18.3±4.52	17.9±4.15	0.751
Total cholesterol (mmol/L)	4.3±1.00	4.3±1.13	4.0±1.00	0.024
Low density lipoprotein cholesterol (mmol/L)	2.7±0.85	2.8±1.01	2.5±0.85	0.051
High density lipoprotein cholesterol (mmol/L)	1.3±0.28	1.2±0.33	1.1±0.31	0.011
Triglycerides (mmol/L)	1.1±0.35	1.1±0.33	1.1±0.30	0.758
fasting blood glucose (mmol/L)	4.7±0.53	4.7±0.49	4.8±0.58	0.163
Total protein (g/L)	66.1±7.92	65.5±4.75	64.8 <u>+</u> 4.83	0.167
Creatinine (umol/L)	63.0±16.60	67.0±14.45	68.2±16.77	0.036
Urea nitrogen (mmol/L)	5.2±1.38	5.3±1.51	5.4±1.41	0.528
High-sensitivity C-reactive protein (mg/L)	1.2±0.95	1.3±1.02	3.1±2.65	<0.001
Coronary artery calcification score	31.6+82.10	73.3±125.6	122.9+135.9	<0.001


Table 1. The clinical and laboratory characteristics of all subjects according to serum CA125 concentrations tertiles.

ACEI or ARB, Beta- blockers, Ca channel blockers and Antidiabetics mean medication use in different category.

The correlations between serum CA125 and age, BMI, BUN, HDL-C, TP, Cr, and hs-CRP (r=0.217, p<0.001; r=0.251, p<0.001; r=0.118, p=0.028; r=-0.185, p<0.001; r=-0.113, p=0.036, r=0.082, p=0.001; r=0.293, p<0.001) in all subjects. Interesting, we found a positive correlation between serum CA125 and CAC score (r=0.319, p<0.001) in all participants. Because serum CA125 levels differed in females and males, we divided all subjects into female and male for assessment of correlations. Serum CA125 concentrations were correlated with age, BMI, UN, Cr, and hs-CRP (r=0.232, p=0.001; r=0.328, p<0.001; r=0.142, p=0.018; r=0.120, p=0.045; r=0.229, p=0.001) in women, and were correlated with age, BMI, TP, and hs-CRP (r=0.180, p=0.026; r=0.175, p=0.031; r=0.365, p<0.001) in men. Similarly, the serum concentrations of CA125 were positively correlated with CAC score in

both women and men (r=0.328, p<0.001; r=0.265, p=0.001, respectively).

To control for major potential confounders that might influence the association between serum CA125 and CAC score in the study population, the multiple linear regression analysis used in this study, we used independent variables of sex, age, BMI, ALT, AST, LDL-C, HDL-C, TP, TG, Cr, hs-CRP, diabetes mellitus, hypertension, calcium ion channel blockers, beta-blockers, antidiabetic medications, and cholesterol-lowering therapy, and CAC score was considered as the dependent variable in multiple linear regression analysis. Our results indicated that serum CA125 concentrations were independently related to CAC score in the study population (beta=0.173, p=0.001), and age, sex, diabetes mellitus, and hs-CRP also






Figure 1. CAC score in study population according to the serum CA125 tertiles.

Figure 2. Serum CA125 concentrations of the study population were grouped as calcium-positive or calcium-negative.

	Unstandardized cofficients		Standardized cofficients	t	P-value
	В	Std Error	Beta		
Gender	31.180	10.482	0.126	2.915	0.003
age	3.434	0.375	0.411	9.549	<0.001
Diabetes mellitus	26.649	11.525	0.100	2.313	0.021
High-sensitivity C-reactive protein	12.661	3.166	0.198	3.999	<0.001
Serum CA125	3.160	0.916	0.173	3.450	0.001

Table 2. the relationship between serum CA125 and coronary artery calcification score in multivariable linear regression analysis.

were associated with CAC score in multiple linear regression analysis, as shown in Table 2.

Discussion

We found an independent relationship between increasing serum CA125 concentrations and CAC score after adjustment for multiple confounders in patients without known coronary artery disease, and serum hs-CRP concentrations were found to be associated with CAC score in multiple linear regression analysis.

CA-125 is secreted by the coelomic epithelial cells, including pericardium, peritoneum, pleura, and müllerian epithelium [16]. Higher serum concentrations of CA125 are linked with the presence of serous cavity effusion liver diseases and ovarian carcinoma [17, 18]. It has been reported that serum levels of CA125 are elevated in patients with heart transplantations [19]. Several studies have reported associations between serum CA125 and cardiovascular diseases [13, 14]. Our study revealed that increased CA125 levels are associated with CAC score in the study population. Although the mechanisms for elevated CA125 have not been elucidated, oxidative stress and inflammation may

explain the relationship between serum CA125 with CAC score in our population. The secretion of serum CA125 is stimulated by mechanical stress and inflammation [20]. CAC deposition has been reported to be an indicator of overall plague burden and future cardiovascular events [21]. Atherosclerotic plagues have inflammatory response and activity, and the appearance of calcifications is associated with atherosclerosis in the coronary arteries [22]. There are relationships between multiple classic markers of inflammation and CAC score in patients with and without cardiovascular disease, such as C-reactive protein, tumor necrosis factor, and interleukin-2 [23-25], and these inflammatory markers may be involved with the progression of CAC in the general population. In additional, vascular oxidative stress has been reported to be linked with atherosclerosis in humans with coronary artery disease [26,27], and the increased oxidative stress can promote and accelerate excessive intracellular calcium accumulation [28,29], which was associated with CAC scores in our study. Our study also found that serum CA125 is correlated with hs-CRP in the study population; the results agree that inflammation has an influence on serum CA125 concentrations. Thus, we can speculate that inflammation and oxidative stress may be a link in the relationship between serum CA125 and CAC scores in the study population.

2876

Some limitations should be noted in our study. First, patients with symptoms of chest pain were included to assess CAC score by CT scanning; therefore, the extrapolation of study results may be limited in other populations. Second, the determination of causality is not clear in the cross-sectional design. Third, the single-center measurement for all laboratory data may also be an inevitable limitation in the present study. Finally, a larger sample size with cohort study is needed.

References:

- 1. Ardehali R, Nasir K, Kolandaivelu A et al: Screening patients for subclinical atherosclerosis with noncontrast cardiac CT. Atherosclerosis, 2007; 192: 235–42
- Rumberger JA, Brundage BH, Rader DJ et al: Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc, 1999; 74: 243–52
- Sangiorgi G, Rumberger JA, Severson A et al: Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: A histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol, 1988; 31: 126–33
- Williams MC, Murchison JT, Edwards LD et al: Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014; 69(8): 718–23
- 5. Bast RC Jr., Feeney M, Lazarus H et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 1981; 68: 1331–37
- Wexler L, Brundage B, Crouse J et al: Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation, 1996; 94: 1175–92
- Rumberger JA, Simons DB, Fitzpatrick LA et al: Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation, 1995; 92: 2157–62
- Chowdhury MA, Xiubin Z, Wei H, Chenghao G: Cancer antigen-125 and ICAM-1 are together responsible for ascites in liver cirrhosis. Clin Lab, 2014; 60(4): 653–58
- 9. Santulli P, Streuli I, Melonio I et al: Increased serum cancer antigen-125 is a marker for severity of deep endometriosis. J Minim Invasive Gynecol, 2015; 22(2): 275–84
- 10. Karaman E, Karaman Y, Alkış İ et al: Maternal serum CA-125 level is elevated in severe preeclampsia. Pregnancy Hypertens, 2014; 4(1): 29–33
- 11. Cebesoy FB, Balat O, Dikensoy E et al: CA-125 and CRP are elevated in preeclampsia. Hypertens Pregnancy, 2009; 28(2): 201–11
- Kouris NT, Zacharos ID, Kontogianni DD et al: The significance of CA125 levels in patients with chronic congestive heart failure Correlation with clinical and echocardiographic parameters. Eur J Heart Fail, 2005; 7: 199–203
- Sekiguchi H, Shimamoto K, Takano M et as: Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women. Heart, 2017; 103(17): 1368–73
- 14. Kaya H, Zorlu A, Yucel H et al: Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients. Acta Cardiol, 2016; 71(1): 61–66

Conclusions

The present data suggest that serum CA125 concentrations are correlated with CAC scores in the population without known coronary artery disease, and serum CA125 may be considered as a marker to estimate CAC in the study population.

Conflicts of interest

None.

- Gauss S, Klinghammer L, Steinhoff A et al: Association of systemic inflammation with epicardial fat and coronary arterycalcification. Inflamm Res, 2015; 64(5): 313–19
- Barbieri RL, Niloff JM, Bast RC Jr. et al: Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril, 1986; 45: 630–34
- Núñez J, Sanchis J, Bodi V et al: Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J, 2010; 31: 1752–63
- 18. Molina R, Filella X, Bruix J et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem, 1991; 37: 1379–83
- 19. Nägele H, Bahlo M, Klapdor R et al: CA 125 and its relation to cardiac function. Am Heart J, 1999; 137: 1044–49
- 20. Halila H, Stenman UH, Seppälä M: Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer, 1986; 57: 1327–29
- 21. Alexopoulos N, Raggi P: Calcification in atherosclerosis. Nat Rev Cardiol, 2009; 6: 681–88
- 22. Burke AP, Virmani R, Galis Z et al: What is the pathologic basis for new atherosclerosis imaging techniques? J Am Coll Cardiol, 2003; 41: 1874–86
- 23. Sung KC, Cho EJ, Lim YH et al: HDL-C levels modify the association between C-reactive protein and coronary artery calcium score. Nutr Metab Cardiovasc Dis, 2014; 24(11): 1240–45
- 24. Dabek J, Swiderski R, Głogowska-Ligus J, Pysz P: Transcriptional activity of tumour necrosis factor α (TNF-α) in patients with subclinical coronary atherosclerosis – preliminary results. Folia Biol (Praha), 2012; 58(5): 209–14
- Damluji AA, Ramireddy A, Al-Damluji MS et al: Association between antihuman heat shock protein-60 and interleukin-2 with coronary artery calcium score. Heart, 2015; 101(6): 436–41
- Guzik TJ, Chen W, Gongora MC et al: Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol, 2008; 52(22): 1803–9
- Ifedili IA, Bob-Manuel T, Bolorunduro O et al: Complete revascularization of simultaneous multiple culprit lesions ina septuagenarian with ST-elevation myocardial infarction. Am J Case Rep, 2016; 17: 997–1001
- 28. Zia AA, Kamalov G, Newman KP et al: From aldosteronism to oxidative stress: The role of excessive intracellular calcium accumulation. Hypertens Res, 2010; 33(11): 1091–101
- Gao L, Cao Z, Zhang H: Efficacy and safety of thrombectomy combined with intracoronary administration of tirofiban in ST-segment elevation myocardial infarction (STEMI). Med Sci Monit, 2016; 22: 2699–705